Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

atrial fibrillation - prevention - patients without history of AF (primary prevention)  


Related trials

GISSI HF (subgroup and ancillary study), 2009 - rosuvastatin vs placebo

ARMYDA-3, 2006 - atorvastatin vs placebo

Chello, 2006 - atorvastatin vs placebo

LIFE, 2005 - losartan vs atenolol

CHARM, 2005 - candesartan vs placebo

Val-HeFT, 2003 - valsartan vs placebo

GISSI-3, 2003 - lisinopril vs placebo

SOLVD, 2003 - enalapril vs placebo

MIRACL, 2001 - atorvastatin vs placebo

TRACE, 1999 - trandolapil vs placebo

VA HIT, 1999 - gemfibrozil vs placebo



See also:

  • All atrial fibrillation clinical trials
  • All clinical trials of prevention
  • All clinical trials of candesartan
    		•  

    CHARM study, 2005

    Treatments

    Studied treatment candesartan
    Control treatment placebo

    Patients

    Patients Heart failure
    Inclusion criteria sinus rhythm at baseline

    Method and design

    Randomized effectives 3225 / 3221 (studied vs. control)
    Follow-up duration 3.17 y


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    atrial fibrillation

    177 / 3225
         215 / 3221
         0,82 [0,68;1,00]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    atrial fibrillation 177 / 3225 (5,5%) 215 / 3221 (6,7%) 0,82 [0,68;1,00]   11053 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11053: Anand K, Mooss AN, Hee TT, Mohiuddin SMMeta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.Am Heart J 2006;152:217-22

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    atrial fibrillation 5,49% 6,67% -11,9‰


    Reference(s)

    Trials register # NA
    • McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.. Lancet 2003;362:767-71
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend